<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398225</url>
  </required_header>
  <id_info>
    <org_study_id>405-201-00010</org_study_id>
    <nct_id>NCT04398225</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in&#xD;
      pediatric subjects with ADHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal peak plasma concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) on day 14</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance and apparent volume of distribution of centanafadine on Day 14</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (9-12 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (6-8 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (4-5 y)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centanafadine</intervention_name>
    <description>Extended release capsule</description>
    <arm_group_label>Cohort 1 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 2 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 3 (9-12 y)</arm_group_label>
    <arm_group_label>Cohort 4 (6-8 y)</arm_group_label>
    <arm_group_label>Cohort 5 (4-5 y)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 4 to 12 years of age, inclusive, at the time of informed&#xD;
             consent/assent.&#xD;
&#xD;
          -  Subjects must weight â‰¥ 13 kg.&#xD;
&#xD;
          -  Subjects with a diagnosis of any ADHD subtype based on Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, 5th edition (DSM-5) criteria and confirmed by the&#xD;
             Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid).&#xD;
&#xD;
          -  Subject is judged by the investigator to be clinically stable, and has not had any&#xD;
             psychiatric hospitalizations within the past 12 weeks.&#xD;
&#xD;
          -  Subjects and their caregivers must be able and willing to utilize the AiCure Platform&#xD;
             for each daily dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a clinical presentation or history that is consistent with delirium,&#xD;
             dementia, amnesia, or other cognitive disorders; subjects with psychiatric symptoms&#xD;
             that are better accounted for by another psychiatric or general medical condition(s)&#xD;
             or direct effect of a substance.&#xD;
&#xD;
          -  Subjects with developmental disorders, such as Autism Spectrum Disorder.&#xD;
&#xD;
          -  Subjects with a history of at least mild intellectual disability as determined by IQ &lt;&#xD;
             70, clinical evidence, or a social or school history that is suggestive of&#xD;
             intellectual disability.&#xD;
&#xD;
          -  Subjects with hypothyroidism or hyperthyroidism (unless condition has been stabilized&#xD;
             with medications for at least 90 days prior to first dose of IMP) or an abnormal&#xD;
             result for free T4 at screening.&#xD;
&#xD;
          -  Subjects who currently have clinically significant neurological, dermatological,&#xD;
             hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or&#xD;
             gastrointestinal disorders such as any history of myocardial infarction, congestive&#xD;
             heart failure, HIV seropositive status/AIDS, or chronic hepatitis B or C.&#xD;
&#xD;
          -  Subjects with insulin dependent diabetes mellitus (i.e. any subjects using insulin)&#xD;
&#xD;
          -  Subjects with epilepsy, Tourette's Disorder, or a history of seizures or a history of&#xD;
             severe head trauma or cerebrovascular disease.&#xD;
&#xD;
          -  Any major surgery within 30 days prior to the first dose of IMP.&#xD;
&#xD;
          -  Any history of significant bleeding or hemorrhagic tendencies.&#xD;
&#xD;
          -  Blood transfusions within 30 days prior to the first dose of IMP.&#xD;
&#xD;
          -  Subjects who have supine or standing diastolic blood pressure, after resting for at&#xD;
             least 5 minutes, &gt; 80 mmHg.&#xD;
&#xD;
          -  Subjects who participated in a clinical trial and were exposed to IMP within the last&#xD;
             30 days prior to screening or who participated in more than 2 interventional clinical&#xD;
             trials within the past year. Subjects who have had any previous exposure to&#xD;
             centanafadine.&#xD;
&#xD;
          -  Subjects with a history of true allergic response to a medication or a history of&#xD;
             dermatologic adverse reactions or anaphylaxis secondary drug exposure.&#xD;
&#xD;
          -  Subjects with a history of allergic reaction or known or suspected sensitivity to any&#xD;
             substance that is contained in the IMP formulation.&#xD;
&#xD;
          -  Subjects who do not tolerate venipuncture or have poor venous access that would cause&#xD;
             difficulty for collecting blood samples.&#xD;
&#xD;
          -  Consumption of alcohol and/or food and beverages containing methylxanthines, foods&#xD;
             known to affect CYP1A2 (e.g. charbroiled or pan-fried meats and cruciferous&#xD;
             vegetables) within 72 hours prior to dosing.&#xD;
&#xD;
          -  Relative of the trial site employees cannot participate in the trial.&#xD;
&#xD;
          -  Siblings, other family members, and those having the same place of residence as the&#xD;
             subject are also excluded from the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otsuka Call Center</last_name>
    <phone>844-687-8522</phone>
    <email>OtsukaUS@druginfo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding sites, contact 844-687-8522</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com</ipd_access_criteria>
    <ipd_url>https://clinical-trials.otsuka.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

